Oklahoma University Cancer Institute

Site:	Oklahoma University Cancer Institute
Address:
City:	Oklahoma City
State:	OK
Zip:	73104
Country:	USA

Phase	Trial	Trial Status	Site Status	Drug	NCT#
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
1	Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506) + Moxifloxacin	NCT01339104
2	A Phase II Study of IMC-A12 in Children With Relapsed/Refractory Solid Tumors	Does not allow GIST	Active	IMC-A12	NCT00831844
1	A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors	Completed	Closed	GDC-0941 + GDC-0973	NCT00996892
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501